Riccardo Bertini

This inventor holds 22 USPTO granted patents, plus 8 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Dompe Pha.r.ma S.p.a., Dompe S.p.a., Dompé Farmaceutici S.p.a.. Active years: 2000-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Riccardo Bertini. Retrieved from https://idiyas.com/inventor/riccardo-bertini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22

% Patents Active = 50.0

CIPO Patents = 8

EPO Patents = 8 (Patent Applications = 1)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 28(Granted Patents)

Location History:

Poggio Piceaze, IT (2000)
L'Aquila AQ, IT (2010)
L'Aquila, IT (2005 - 2016)
Milan, IT (2016)

Company Filing History:

10 out of 14

Dompe Pha.r.ma S.p.a.

Dompé Farmaceutici S.p.a.

patents

4. 4 out of 834,601

Other

patents

Years Active: 2000-2016

Loading Chart...

Areas of Expertise:

Aminoalkylamides

Arylpropionic Acids

Inflammatory Diseases

Pharmaceutical Compositions

Neutrophil Chemotaxis

Sulfonamides

Amides

Chiral Arylketones

2-Phenylpropionic Acid

Leucocyte Activation

Quaternary Ammonium Salts

R-2-Aryl-Propionic Acids

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9493402 - Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells (2016-11-15),

2. 9328057 - Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases (2016-05-03),

3. 8871784 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them (2014-10-28),

4. 8648110 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them (2014-02-11),

5. 8293788 - 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them (2012-10-23),

6. 8288368 - Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells (2012-10-16),

7. 8063242 - 2-aryl-propionic acids and pharmaceutical compositions containing them (2011-11-22),

8. 8039656 - 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them (2011-10-18),

9. 8026367 - (R)-arylalkylamino derivatives and pharmaceutical compositions containing them (2011-09-27),

10. 7939521 - 2-arylpropionic acid derivatives and pharmaceutical compositions containing them (2011-05-10),

11. 7868046 - (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them (2011-01-11),

12. 7776909 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them (2010-08-17),

13. 7737139 - Sulfonic acids, their derivatives and pharmaceutical compositions containing them (2010-06-15),

14. 7705050 - Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils (2010-04-27),

15. 7674806 - Amidines and derivatives thereof and pharmaceutical compositions containing them (2010-03-09),

Title: Riccardo Bertini: Innovator in Pharmaceutical Patents from L'Aquila, Italy

Introduction

Riccardo Bertini is an accomplished inventor based in L'Aquila, Italy, with a remarkable portfolio of 22 patents. His innovative contributions primarily focus on pharmaceutical preparations aimed at treating inflammatory diseases. Through his work, he has demonstrated a commitment to advancing therapeutic options and improving patient care.

Latest Patents

Among Bertini's latest patents is a significant invention involving omega-aminoalkylamides of R-2-aryl-propionic acids. This discovery relates to compounds that serve as inhibitors of chemotaxis for polymorphonucleate and mononucleate cells. The pharmaceutical preparations developed from his compounds play a crucial role in preventing and treating tissue damage from excessive recruitment of immune cells at inflammatory sites.

His innovations include the R enantiomers of omega-aminoalkylamides which inhibit the chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and other chemotactic proteins. Furthermore, Bartini’s compounds have dual functionality, acting as inhibitors of both C5a-induced chemotaxis and IL-8-induced chemotaxis of polymorphonuclear leukocytes. Another notable patent involves chiral arylketones, which serve as therapeutic agents for treating neutrophil-dependent inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis, as well as addressing damages caused by ischemia and reperfusion.

Career Highlights

Riccardo Bertini has made substantial impacts in the pharmaceutical sector through his association with companies like Dompe Pharma S.p.A. and Dompe S.p.A. His work at these institutions has leveraged innovative scientific research to develop practical applications that address severe health challenges, significantly advancing the field of pharmacology.

Collaborations

Throughout his career, Bertini has collaborated with notable professionals, including Marcello Allegretti and Maria Candida Cesta. These partnerships have enriched his research endeavors, contributing to the advancement of medical therapies and broadening the implications of his patents in various healthcare contexts.

Conclusion

Riccardo Bertini stands out as a prominent figure in the realm of pharmaceutical inventions, with a strong portfolio that reflects his innovative spirit and dedication to improving health outcomes. His ongoing research and developments continue to pave the way for advancements in treatments for inflammatory diseases, showcasing the vital role of inventors in fostering progress in medicine.

Profile summary based on public USPTO records.